Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 8, 2000, Pages 2052-2060

  Weller, Stephen ^a   Radomski, Kristine M ^a,b   Lou, Yu ^a   Stein, Daniel S ^a  

^a GLAXOSMITHKLINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALAISE; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL;

EID: 0033929197     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2052-2060.2000     Document Type: Article

References (19)

1. Akaike, A. 1978. Posterior probabilities for choosing a regression model. Ann. Inst. Math. Stat. 30:A9-A14.
2. Beal, S. L., and L. B. Sheiner. 1989. NONMEM user's guide. University of California, San Francisco, San Francisco.
3. Daluge, S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective, anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
4. Division of AIDS, National Institute of Allergy and Infectious Diseases. 1996. Division of AIDS table for grading severity of adult adverse experiences. National Institute of Allergy and Infectious Diseases, Rockville, Md.
5. Drusano, G. L., G. J. Yuen, J. S. Lambert, M. Seidlin, R. Dolin, and F. T. Valentine. 1992. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. Ann. Intern. Med. 116:562-566.
6. Drusano, G. L., F. M. Balis, S. R. Gitterman, and P. A. Pizzo. 1994. Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob. Agents Chemother. 38:1726-1731.
7. Drusano, G. L., and D. S. Stein. 1998. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Antimicrob. Agents. Chemother. 42:358-361.
8. Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89, Antimicrob. Agents. Chemother. 41:1099-1107.
9. Flexner, C., C. van der Horst, M. A. Jacobson, et al. 1994. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J. Infect. Dis. 170:1394-1403.
10. Gibaldi, M., and D. Perrier. 1982. Multiple dosing, first order absorption, p. 132-142. In Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
11. Hughes, W, J. A. McDowell, J. Shenep, P. Flynn, M. W. Kline, R. Yogev, W. Symonds, Y. Lou, and S. Hetherington. 1999. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob. Agents. Chemother. 43:609-615.
12. Kumar, P. N., D. E. Sweet, J. A. McDowell, W. Symonds, Y. Lou, S. Hetherington, and S. LaFon. 1999. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 43:603-608.
13. 14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single, oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents. Chemother. 43:2855-2861.
14. McDowell, J. A., Y. Lou, W. S. Symonds, D. S. Stein, and K. Muir. 2000. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 44:2061-2067.
15. Saag, M. S., A. Sonnerborg, R. A. Torres, D. Lancaster, B. G. Gazzard, R. T. Schooley, C. Romero, D. Kelleher, W. Spreen, S. LaFon, and the Abacavir Phase 2 Clinical Team. 1998. Antiretroviral effect and safety of abacavir and abacavir in combination with zidovudine in HIV-infected adults. AIDS 12: F203-F209.
16. Staszewski, S., C. Katlama, T. Harrer, P. Massip, P. Yeni, A. Cutrell, S. M. Tortell, P. R. Harrigan, H. Steel, E. R. Lanier, and G. Pearce. 1998. A dose-ranging study to evaluate the safety and efficacy of three doses of abacavir (1592U89) alone or in combination with zidovudine and lamivudine in antiretroviral treatment naive subjects. AIDS 12:F197-F202.
17. + lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J. Infect. Dis. 165:352-363.
18. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents. Chemother. 41:1094-1098.
19. Wang, L. H., G. E. Chittick, and J. A. McDowell. 1999. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with HIV infection. Antimicrob. Agents. Chemother. 43:1708-1715.